Published in Blood on October 07, 2014
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. PLoS One (2016) 1.40
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia (2012) 0.88
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood (2016) 0.87
Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int (2015) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment. Oncotarget (2015) 0.81
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene (2015) 0.80
Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia (2017) 0.79
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget (2016) 0.78
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget (2016) 0.77
Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res (2017) 0.75
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol (2016) 0.75
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood Cancer J (2017) 0.75
SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma. EBioMedicine (2014) 0.75
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget (2016) 0.75
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J (2016) 0.75
The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int (2016) 0.75
New insights into malignant B-cell disorders. Biomed Res Int (2015) 0.75
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep (2016) 0.75
Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus. Adv Mater (2016) 0.75
VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. Onco Targets Ther (2017) 0.75
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol (2017) 0.75
BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. Oncotarget (2017) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica (2017) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr (1961) 10.35
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
The use of mixture models for the analysis of survival data with long-term survivors. Biometrics (1982) 3.02
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood (2011) 2.74
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood (2011) 2.58
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood (2009) 2.08
The role of complete response in multiple myeloma. Blood (2009) 1.91
Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol (2010) 1.91
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood (2009) 1.56
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res (2007) 1.53
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia (2013) 1.51
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol (2006) 1.44
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol (2014) 1.44
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia (2014) 1.43
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood (2010) 1.26
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood (2014) 1.19
Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev (2006) 1.16
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood (2014) 1.13
The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol (2007) 1.09
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia (2013) 1.08
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia (2008) 1.01
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood (2013) 1.00
Cure of myeloma: hype or reality? Bone Marrow Transplant (2005) 0.95
Curability of multiple myeloma. Bone Marrow Res (2012) 0.94
Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol (2001) 0.92
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia (2013) 0.90
Serial exome analysis of disease progression in premalignant gammopathies. Leukemia (2014) 0.87
Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia (2013) 0.84
Toward a cure for multiple myeloma? N Engl J Med (1991) 0.83
Going with the flow, and beyond, in myeloma. Blood (2008) 0.81
Pursuing the curative blueprint for early myeloma. Blood (2013) 0.81
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment. Biomark Res (2014) 0.79
Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk (2013) 0.79
Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145. Haematologica (2013) 0.79
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. Expert Rev Anticancer Ther (2014) 0.76
The future of autologous stem cell transplantation in myeloma. Blood (2014) 0.99